Diamyd Medical

9.47

SEK

-1.87 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Diamyd Medical is a diabetes company. The company develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.

Market cap

1.3B SEK

Turnover

3.1M SEK

Revenue

130K

EBIT %

-112,746.15 %

P/E

-

Dividend yield-%

-

Financial calendar

25/6

2025

Interim report Q3'25

8/10

2025

Annual report '25

All

Research

Webcasts

Press releases

3rd party

ShowingAll content types

Regulatory press release6/16/2025, 1:05 PM

Diamyd Medical AB: Diamyd Medical deltar i två viktiga diabetes-evenemang i USA denna vecka

Regulatory press release6/16/2025, 1:05 PM

Diamyd Medical AB: Diamyd Medical to participate in two key US diabetes events

Regulatory press release5/19/2025, 9:30 AM

Diamyd Medical AB: Diamyd Medical appoints Niklas Axelsson as CFO

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/19/2025, 9:30 AM

Diamyd Medical AB: Diamyd Medical utser Niklas Axelsson till CFO

Regulatory press release5/15/2025, 1:10 PM

Diamyd Medical AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated

Regulatory press release5/15/2025, 1:10 PM

Diamyd Medical AB: Justering av antal aktier och aktiekapital i Diamyd Medical, tillförs ytterligare 1,6 MSEK än tidigare kommunicerat

Press release5/9/2025, 5:02 AM

Carnegie Access: Diamyd Medical: Targeting the root of autoimmune diabetes

Press release5/5/2025, 12:45 PM

Impala Nordic: Diamyd Medical - Framgångsrik kapitalanskaffning

Regulatory press release5/5/2025, 6:45 AM

Diamyd Medical AB: Diamyd Medical har utökat den nyss avslutade företrädesemissionen med en riktad nyemission om 41,6 MSEK

Regulatory press release5/5/2025, 6:45 AM

Diamyd Medical AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million

Regulatory press release4/30/2025, 6:50 PM

Diamyd Medical AB: Diamyd Medical offentliggör slutgiltigt utfall i övertecknad företrädesemission: 224 miljoner SEK

Regulatory press release4/30/2025, 6:50 PM

Diamyd Medical AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million

Regulatory press release4/30/2025, 6:30 AM

Diamyd Medical AB: Diamyd Medical uppdaterar det preliminära utfallet och utnyttjar utökningsemissionen efter övertecknad företrädesemission, tillförs cirka 224 MSEK

Regulatory press release4/30/2025, 6:30 AM

Diamyd Medical AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million

Regulatory press release4/29/2025, 4:15 PM

Diamyd Medical AB: Diamyd Medicals företrädesemission har preliminärt tecknats till 95 procent och tillförs därmed cirka 198 MSEK

Regulatory press release4/29/2025, 4:15 PM

Diamyd Medical AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million

Regulatory press release4/28/2025, 10:10 AM

Diamyd Medical AB: Sista teckningsdag i Diamyd Medicals företrädesemission

Regulatory press release4/28/2025, 10:10 AM

Diamyd Medical AB: Last day of the subscription period in Diamyd Medicals rights issue

Regulatory press release4/28/2025, 9:10 AM

Diamyd Medical AB: Europa beviljar Diamyd Medical patent för precisionsmedicin med insulinantigen vid autoimmun diabetes

Regulatory press release4/28/2025, 9:10 AM

Diamyd Medical AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes

Forum discussions

Diamyd Medical är ett bolag inne i en händelserik period. Detta är Diamyd i korta drag hämtat från deras hemsida: Med huvudprodukten Diamyd har man tagit steg där Diamyd är ett intressant läkemedel som verkar ha potential att förbättra blodsockerkontrollen och minska komplikationerna...

4/12/2024, 9:25 AM

by Jesper Hagman

5

Diamyd meddelade igår det preliminära utfallet i företrädesemission vilket indikerar att cirka 4,2 miljoner units, motsvarande cirka 44 procent av företrädesemissionen tecknats med stöd av uniträtter. Inderes Diamyd Medical AB: Diamyd Medical offentliggör preliminärt utfall i bolagets...

4/17/2024, 6:25 AM

by Jesper Hagman

2

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.